The Price of a Life Is Not Printed on the Box

On 27 October, the Supreme Court heard a plea on medicine prices. During the hearing, the bench told a story. A medicine distributor’s wife was being treated for cancer at a well-known private hospital. He told the hospital he could buy her chemotherapy injection for Rs 11,000. The hospital refused to use his injection and billed Rs 1.3 lakh.

The bench asked the Center to justify the gap. The Court has reserved its verdict. The hospital was not named, and the story is as the judges told it, not a proven finding. But the story matters because every Indian family that has paid a hospital bill will find it believable.

One man knew the real price

Look at what made this story possible. The man was a distributor, so he knew what the drug cost. Most patients do not. A family in a hospital corridor at night is not comparing prices. They sign the forms and pay, because the only other choice is to risk a life.

A market works when the buyer can compare, question and refuse. A cancer patient in the middle of treatment can do none of these. The hospital also prescribes the drug and sells it. The buyer has no time, no information and no choice.

Three prices, one box

A medicine has at least three prices. The dealer price is what a trader pays. The MRP is the number printed on the box. The hospital bill is what the patient pays. These are not the same, and the gaps between them are large.

The Court gave other examples in the same hearing. A drip line that costs a retailer Rs 15 was billed at Rs 250. A medicine bought for Rs 2,700 carried an MRP of Rs 27,000. The bench asked a simple question: who fixes the MRP? A cost is a fact. An MRP is a choice.

The fair case for hospitals

Hospitals do have real costs. They pay for trained staff, cold storage, equipment and the risk of wasted stock. There is also a safety argument for refusing outside medicine. A hospital cannot always confirm where a drug was stored or whether it is genuine.

These points explain some of the gap. They do not explain a bill of nearly twelve times the dealer price. The bench said a hospital can survive through other means, and did not need this. That is hard to dispute.

The government’s part

The Centre told the Court that it capped trade margins on anti-cancer medicines at 30 per cent of MRP. It expects this to save patients about Rs 2,500 crore every year. That is a real step, and it should be said plainly.

But the Court asked why such a step took so long, and it called the government’s approach too wayward. A patient who pays Rs 1.3 lakh for a Rs 11,000 injection is not helped by a policy that arrives years late.

What should change

India does not need to guess at the answers. Three steps would help.

• Hospital bills should show the price of each medicine and consumable in plain terms, so a family can see what it is paying for.
• Price controls should cover more essential drugs, especially for cancer.
• Patients should have a safe, verified way to bring their own medicine when they can get it for less.

None of these ends private healthcare. They only give the patient what the distributor had: the knowledge to ask a question.

The real cost

In India, a serious illness can push a middle-class family into debt within months. Families sell land, gold and homes to pay for treatment. When a price has no honest link to a cost, that money is not only expensive. It is taken from people at the moment they are least able to say no.

The same vial was worth Rs 11,000 to one man and Rs 1.3 lakh to another. The medicine was the same. Only the fear was different.

A fair system does not charge for fear.

Comments

comments